Objective This review aims to provide an overview of the current knowledge available on the nature and extent of the relationship between external-beam radiotherapy (RT) and fear of cancer recurrence (FoR).
| BACKGROUND
Radiotherapy (RT) is a treatment frequently used for cancer patients involving the use of high-energy radiation. 1 Almost a half to two-thirds of cancer patients will have RT as part of their treatment plan (adjuvant treatment), and almost 75% of patients who received RT are treated to cure the cancer, rather than to relieve symptoms such as pain. 2 Radiotherapy is delivered in 2 ways-external to the body by a machine (external-beam RT) or within the body by judicious siting of radioactive material (brachytherapy [BT] ). According to the latest data, about 88% of patients received RT, while the remaining 12% of patients received BT.
1,2
The fear of recurrence (FoR) is common among cancer patients and survivors. 3 Fear of recurrence is considered to persist long after the termination of treatment and into the chronic stage of survivorship. 3 Fear of recurrence is reported by 33% to 96% of cancer patients [4] [5] [6] [7] and may predict poorer quality of life outcomes up to 6 years after diagnosis. 8 Cancer patients who suffer from high FoR report negative behavior change (eg, avoidance behavior and excessive personal checking behaviors), 9 increased health service use, 10 inability to plan for the future, 11 and significant psychological distress, such as depression, anxiety, and post-traumatic stress symptoms. 4, [12] [13] [14] In recently published studies, a variety of factors were found to be associated with patients' FoR level. 3 Demographic characteristics such as female gender, young age, and a higher level of education have been reported to be related with higher FoR. In addition, studies have shown that white women are more likely to have higher worry levels than African Americans. [15] [16] [17] [18] [19] [20] [21] Various treatment characteristics, such as having received a mastectomy or chemotherapy and having more physical symptoms, have been identified as strong predictors of FoR. However, these findings are not always consistent. 16, 17, [21] [22] [23] For example, Mellen et al 24 and Leake et al 22 reported that treatment type (chemotherapy, surgery, or RT) was not related to patient's FoR. Llewellyn et al 8 reported that FoR had no association with any sociodemographic or treatment factors. focus solely on RT, as opposed to, or in combination with BT, is that RT is the most frequent medium of treatment using ionizing radiation, which involves specific units including resource intensive physical and capital environments in the design of clinics and specialist units, while BT is more novel, delivered on a smaller scale and with less public awareness of the procedure. There may be value to the health provider team to learn of patient reaction to their treatment and enable additional avenues of intervention to assist patients through the experience of a common treatment delivery in cancer care.
The aim of this study is to conduct a systematic overview and meta-analysis of FoR-RT-related quantitative studies to test the association between cancer patient's FoR and the receipt of RT. By systematically summarizing current knowledge, an indication of the influence of RT on FoR may be provided.
2 | METHOD
| Literature search
The study was conducted in accordance with the PRISMA guidelines for a systematic review and meta-analysis. 27 The Ovid MEDLINE, PubMed, and Ovid EMBASE (1974 to May 2016) databases were utilized. The key search terms were as follows: cancer/carcinoma/ neoplasm, fear/worry/concern, recurrence/progression/return, and radiation/radiotherapy/radiation therapy. Searching was performed using the OR and AND functions. The detailed search strategy is outlined in supplementary Table S1 . The reference lists of identified review articles as well as all included studies were also screened manually for any additional relevant studies. No restrictions were placed on publication date.
| Inclusion and exclusion criteria
To be included in the review, references had to (a) be published in a The quality of each included study was assessed using QualSyst criteria (Standard Quality Assessment Criteria for quantitative studies, 28 see Table S2 ). Items were scored on the specific criteria (yes = 2, partial = 1, and no = 0). A summary score was calculated for each paper 
| Statistical analysis
On completion of the systematic review, a quantitative meta-analytic approach was applied. The program Comprehensive Meta-analysis was used. 29 The effect size was calculated by applying routines to derive a correlation (r) with accompanying 95% confidence intervals (CIs). The effect size was calculated by r but not the Hedges g because several of the included articles 20, 30, 31 had very large sample sizes. The corresponding authors of articles with incomplete data were contacted by email to obtain the required data unavailable in the published article. Studies for which the corresponding authors could not be reached were subsequently excluded from the meta-analysis.
Statistical heterogeneity among the articles was reported by the Q statistic, a P value less than .10 or an I 2 value greater than 50% was considered as substantial heterogeneity. 29 If substantial heterogeneity was observed, the correlation will be calculated according to the random-effects model; otherwise, the results would be calculated based on the fixed-effects model. The selection of the computational model was based on the understanding of the underlying distribution. Under the fixed-effect model, we assumed that the true effect size was the same in all studies, while in the random-effect meta-analysis, we expected the effect size to be similar but not identical across studies.
True effect sizes were assumed to be normally distributed under this model.
29
A subgroup analysis based on the cancer site was performed (breast cancer versus other types of cancer). The percentage of breast cancer patients treated with RT has increased substantially during the past 2 decades. 32 According to the best available evidence, RT would be recommended in 83% (95% CI, 82%-85%) of patients with breast cancer. 33 In the articles included in the meta-analysis, over half of the patients were diagnosed as having breast cancer (5680 of 9567 patients, 59%). Therefore, the subgroups breast vs other cancers were chosen pragmatically, to investigate the potential value of cancer type on the relationship between RT and FoR. In addition, the Rosenthal "fail-safe N" procedure was adopted to estimate the number of negative studies that would be required to overturn the total aggregated result. Funnel plot and the Egger regression intercept test were also performed in this review to assess publication bias.
3 | RESULTS
| Characteristics of included studies
The search process is shown in Figure S1 . The literature search of 3 databases identified 751 references. Duplicates were excluded revealing 356 titles. Examination of abstracts for appropriateness left 55
articles. After retrieving full texts and further assessment, 25 studies were included in the systematic review. All of them were evaluated using the QualSyst criteria, and none of them had the score of limited quality (see Table 1 ). However, 10 studies were excluded from further meta-analysis (1 prevalence rate study, 34 2 longitudinal studies, 35, 36 and 1 strong outlier in funnel plot, 37 and 6 did not report specific statistic values 16, 22, 24, [38] [39] [40] ). Therefore, 15 articles were finally included in the meta-analysis. ). Heterogeneity test showed that the Q value of this review was 29.46, the P value was less than .1, and the I 2 value was greater than 50% (P = .009; I 2 = 52.482); therefore, a random-effect model was used. By using random-effect weights, the summary estimate of the correlation was 0.053 with a 95% CI of 0.021 to 0.085. The Z value was 3.275, and the P value was .001 (2 tailed).
Subgroup analysis showed that cancer type was linked to the degree of association; namely, the "other cancer" group showed a statistically significant correlation between RT and FoR (P < .001) while the "breast cancer" group showed a nonsignificant result (P = .538, see Figure 1 ). The correlation value of "other cancer group" (r = 0.089) is significantly higher than that of "breast cancer group" (r = 0.014, P = .001). Additionally, the fail-safe N value, which calculates the number of missing studies that would bring the P value to less than an α of 1.96, was found to equal 64. In the examination of the funnel plot, 15 studies were noticeably distributed symmetrically about the mean effect size (see Figure S2 ). The Egger regression intercept test showed no statistically significant P value (intercept = 0.448, standard error = 0.61, T = 0.74, and P = .48); therefore, we assume that no apparent publication bias was found in this review. are usually chronic and progressive and can be sustained for many years after the end of treatment. 52 Strong evidence was found for an association between residual physical symptoms and elevated FoR. 24 Therefore, it is reasonable to conceive that RT-related symptoms, such as tiredness and skin reaction, might be viewed by patients as a constant reminder of their cancer or be misinterpreted as an indicator of cancer recurrence, which leads to higher FoR score. Also, some patients may believe that the effect of RT may be a risk factor for new malignancies. The results point to the need for patient education Article excluded from the meta-analysis-strong outlier in funnel plot.
about common RT side effects, both before and after RT, to provide patients with sufficient knowledge that they wish to receive. The aim of this additional attention to patient RT health literacy is to diminish FoR development.
Another reason may be patients' doubts about the efficacy of RT.
Owing to the more conservative nature of RT, patients may feel less confident and hold concern that the tumor/cancer still exists inside their body; thus, patients are more likely to report higher FoR. One study 53 has found out that conservative treatment such as endoscopic therapy for esophageal cancer was associated with higher FoR, which may relate to patients' doubts about whether the cancer has been fully have high levels of FoR should be carefully identified and invited into appropriate psychological programs to assist them and help address overall negative effects on health-related quality of life.
| CONCLUSIONS
Although meta-analysis showed a statistically significant association between cancer patient's FoR and the receipt of external-beam radiation treatment, the relationship might not be clinically significant. Further longitudinal studies should be conducted to address the trajectory of FoR over RT in a more detailed way, and standardized validated FoR measurement should be developed and used.
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